INmune Bio Inc.

8.11
0.52 (6.85%)
At close: Apr 02, 2025, 3:59 PM
7.94
-2.10%
After-hours: Apr 02, 2025, 07:55 PM EDT

INmune Bio Statistics

Share Statistics

INmune Bio has 22.93M shares outstanding. The number of shares has increased by 34.42% in one year.

Shares Outstanding 22.93M
Shares Change (YoY) 34.42%
Shares Change (QoQ) 19.93%
Owned by Institutions (%) 30.57%
Shares Floating 16.3M
Failed to Deliver (FTD) Shares 12.07K
FTD / Avg. Volume 3.13%

Short Selling Information

The latest short interest is 5.03M, so 22.7% of the outstanding shares have been sold short.

Short Interest 5.03M
Short % of Shares Out 22.7%
Short % of Float 31.92%
Short Ratio (days to cover) 14.58

Valuation Ratios

The PE ratio is -2.24 and the forward PE ratio is -3.92. INmune Bio's PEG ratio is -0.09.

PE Ratio -2.24
Forward PE -3.92
PS Ratio 6733.36
Forward PS 1.3
PB Ratio 2.94
P/FCF Ratio -2.83
PEG Ratio -0.09
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for INmune Bio.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.01.

Current Ratio 3.14
Quick Ratio 3.14
Debt / Equity 0.01
Debt / EBITDA -0.01
Debt / FCF -0.01
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $1.08K
Profits Per Employee $-3.24M
Employee Count 13
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -19.7% in the last 52 weeks. The beta is 1.94, so INmune Bio's price volatility has been higher than the market average.

Beta 1.94
52-Week Price Change -19.7%
50-Day Moving Average 8.43
200-Day Moving Average 6.8
Relative Strength Index (RSI) 50.74
Average Volume (20 Days) 385.68K

Income Statement

In the last 12 months, INmune Bio had revenue of 14K and earned -42.08M in profits. Earnings per share was -2.08.

Revenue 14K
Gross Profit 14K
Operating Income -42.63M
Net Income -42.08M
EBITDA -42.63M
EBIT -42.63M
Earnings Per Share (EPS) -2.08
Full Income Statement

Balance Sheet

The company has 20.92M in cash and 384K in debt, giving a net cash position of 20.54M.

Cash & Cash Equivalents 20.92M
Total Debt 384K
Net Cash 20.54M
Retained Earnings -163.1M
Total Assets 39.56M
Working Capital 15.44M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -33.36M and capital expenditures 0, giving a free cash flow of -33.36M.

Operating Cash Flow -33.36M
Capital Expenditures 0
Free Cash Flow -33.36M
FCF Per Share -1.65
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -304535.71% and -300585.71%.

Gross Margin 100%
Operating Margin -304535.71%
Pretax Margin -300585.71%
Profit Margin -300585.71%
EBITDA Margin -304535.71%
EBIT Margin -304535.71%
FCF Margin -238292.86%

Dividends & Yields

INMB does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for INMB is $23, which is 183.6% higher than the current price. The consensus rating is "Buy".

Price Target $23
Price Target Difference 183.6%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Scores

Altman Z-Score 6.54
Piotroski F-Score 3